10-Q: Raphael Pharmaceutical Inc. Reports Q3 2024 Results: Operating Loss Decreases Amidst Ongoing Clinical Development

Raphael Pharmaceutical Inc. reported a decrease in operating loss for the third quarter of 2024, driven by reduced research and development expenses, as the company continues its clinical development programs.

Summary

• Raphael Pharmaceutical Inc. reported its financial results for the third quarter of 2024, showing a net loss of $326,000, which is an improvement compared to the $725,000 loss in the same period of 2023.
• The company's operating loss decreased to $319,000 for the quarter, down from $729,000 in the prior year, primarily due to lower research and development expenses.
• Research and development expenses decreased by 68.2% to $162,000 for the quarter, while general and administrative expenses also saw a decrease of 28.3% to $157,000.
• For the nine months ended September 30, 2024, the net loss was $1,124,000, compared to $1,406,000 for the same period in 2023.
• The company's cash and cash equivalents stood at $40,000 as of September 30, 2024, a significant decrease from $230,000 at the end of 2023.
• Raphael Pharmaceutical is currently in the pre-clinical development stage for its lead product candidate for rheumatoid arthritis (RA) and is also developing a treatment for hyperinflammatory syndrome and lung inflammation related to COVID-19.
• The company has initiated a proof-of-concept clinical trial in the United States for its RA product candidate, with an estimated timeline of six months to finalize the trial from the recruitment of the first participant.
• The company has not generated any revenue to date and is relying on equity financing and loans to fund its operations.
• Management has expressed substantial doubt about the company's ability to continue as a going concern if additional funding is not secured.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a substantial decrease in cash reserves and management's doubt about the company's ability to continue as a going concern. While there are some positive developments in clinical trials, the overall sentiment is negative due to the company's financial instability.

Positives

• The company's net loss decreased significantly in both the three and nine month periods ending September 30, 2024, compared to the same periods in 2023.
• Operating expenses, including research and development and general and administrative costs, have decreased, indicating improved cost management.
• The company has commenced a proof-of-concept clinical trial in the United States for its RA product candidate, marking a significant step in its clinical development program.
• The company has secured agreements for research and development with Rambam MT, and for CBD oil supply with Wolc, which are crucial for its product development.

Negatives

• The company has not generated any revenue to date and is relying on external funding.
• The company's cash reserves have significantly decreased, raising concerns about its ability to fund ongoing operations.
• Management has expressed substantial doubt about the company's ability to continue as a going concern if additional funding is not secured.
• The company is still in the early stages of development and faces significant risks associated with clinical trials and regulatory approvals.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• There is no guarantee that the company will be able to obtain regulatory approvals for its product candidates.
• The company faces risks associated with clinical trials, including the possibility of unfavorable results or delays.
• The company's success is dependent on the commercial launch and future sales of its product candidates, which are subject to market risks and competition.
• The company is subject to risks related to third-party payor reimbursement for its product candidates.
• The company's research and development efforts may not be successful, and product development may not be completed within the expected timeline.
• The company is subject to risks related to economic weakness, including inflation, or political instability in particular foreign economies and markets.

Future Outlook

The company anticipates needing approximately $0.8 million for research and development activities and $0.6 million for capital expenditures over the next 12 months, and will require significant additional financing in the near future to fund its operations. Management has expressed substantial doubt about the company's ability to continue as a going concern if additional funding is not secured.

Management Comments

• Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity.
• Management has concluded that substantial doubt about the Company's ability to continue as a going concern exists in the event that additional funding does not occur.
• Management plans include raising capital in the United States.

Industry Context

The company operates in the pharmaceutical industry, specifically focusing on cannabinoid-based drug therapies. This is a growing area of research and development, with increasing interest in the potential therapeutic benefits of cannabinoids. The company's focus on rheumatoid arthritis and COVID-19 related inflammation aligns with current medical needs and research trends. However, the industry is highly competitive and subject to strict regulatory requirements.

Comparison to Industry Standards

• Raphael Pharmaceutical is a development stage company with no revenue, which is typical for early-stage biotech firms focused on drug development.
• The company's cash burn rate is high, with a net loss of $1.124 million for the nine months ended September 30, 2024, which is common for companies in the clinical trial phase.
• Compared to other pharmaceutical companies in the cannabinoid space, Raphael is still in the pre-clinical and early clinical trial stages, while some competitors have already achieved regulatory approvals or are in later stages of clinical development.
• Companies like GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) have successfully commercialized cannabinoid-based drugs, setting a benchmark for regulatory approval and commercialization.
• Other companies such as Canopy Growth and Tilray are focused on the broader cannabis market, including recreational use, while Raphael is focused on pharmaceutical applications.
• The company's research collaboration with Rambam Health Care Campus is similar to other biotech companies that partner with academic institutions for research and development.
• The company's reliance on equity financing is typical for early-stage biotech companies, but the need for additional funding raises concerns about its long-term viability.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for dilution through future capital raises.
• Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
• Customers and patients may be impacted by delays in product development or the company's inability to bring its products to market.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will continue its proof-of-concept clinical trial in the United States for its RA product candidate.
• The company will focus on further investigating and refining the formula through continued pre-clinical research.
• The company will seek to raise additional capital to fund its operations.
• The company intends to obtain approvals for its product candidates from the FDA and the Medical Cannabis Unit of the Israeli Ministry of Health, or MOH.
• The company intends to apply for EMA and other countries governmental regulatory agencies approvals for its product candidates.

Key Dates

Keywords

Pharmaceutical, Cannabinoids, CBD, Rheumatoid Arthritis, Clinical Trials, Research and Development, COVID-19, Regulatory Approvals, Financial Results, Operating Loss